Stock CNTG CENTOGENE N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Centogene N.V.

Equities

CNTG

NL0014040206

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.4559 USD -1.11% Intraday chart for Centogene N.V. -17.93% -62.01%
Apr. 02 Centogene Gets Nasdaq Noncompliance Notice MT
Mar. 19 Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Centogene Gets Nasdaq Noncompliance Notice
MT
CENTOGENE Receives Nasdaq Non-Compliance Notice
GL
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics
MT
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
GL
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders
CI
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
GL
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
GL
CENTOGENE Explores Strategic Alternatives
GL
Centogene Explores Strategic Alternatives
CI
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
GL
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration
CI
CENTOGENE Receives French Research Tax Credit Accreditation
GL
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics
CI
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
GL
CENTOGENE Announces Preliminary Full Year 2023 Revenue
GL
Centogene N.V. Provides Earnings Guidance for the Full Year 2023
CI
Centogene N : Minutes for Centogene EGM December 2023
PU
CENTOGENE Announces Voting Results of Extraordinary General Meeting
GL
Centogene N.V. Announces Changes to Supervisory Board
CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNTG Stock
  4. News Centogene N.V.